Search results

Source:

British HIV Association - BHIVA (Remove filter)

DOI: 10.1111/hiv.12136 c 2014 British HIV Association HIV Medicine (2014), 15 (Suppl. 2), 1-92 _______________

Type:

Guidance (Add filter)

Source:

British HIV Association - BHIVA (Remove filter)

c 2015 British HIV Association...

Type:

Guidance (Add filter)

Source:

British HIV Association - BHIVA (Remove filter)

Guideline writing group Michael Brady (Co-chair) Consultant in Sexual Health and HIV, King's College Hospital, London Alison Rodger (Co-chair) Reader...

Type:

Guidance (Add filter)

Source:

British HIV Association - BHIVA (Remove filter)

c 2016 British HIV Association...

Type:

Guidance (Add filter)

Source:

British HIV Association - BHIVA (Remove filter)

DOI: 10.1111/hiv.12106 c 2013 British HIV Association HIV Medicine (2013), 14 (Suppl. 4), 1-71 ________________________________________

Type:

Guidance (Add filter)

Source:

British HIV Association - BHIVA (Remove filter)

These guidelines are dedicated to the memory of Professor Stephen Lawn, a scientist and clinician whose pioneering work helped transform the...

Type:

Guidance (Add filter)

Source:

GOV UK (Remove filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Add filter)

Published by Medicines and Healthcare products Regulatory Agency, 17 December 2020

Fluoroquinolones should only be used after careful benefit-risk assessment and after consideration of other therapeutic options in patients at risk for heart valve regurgitation (incompetence).

Read Summary

Type:

Safety Alerts (Add filter)

Source:

GOV UK (Remove filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Add filter)

Published by Medicines and Healthcare products Regulatory Agency, 21 March 2019

Disabling, long-lasting or potentially irreversible adverse reactions affecting musculoskeletal and nervous systems have been reported very rarely with fluoroquinolone antibiotics. Fluoroquinolone...

Read Summary

Type:

Safety Alerts (Add filter)

Source:

GOV UK (Remove filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Add filter)

Published by Medicines and Healthcare products Regulatory Agency, 14 November 2018

In patients at risk for aortic aneurysm and dissection, fluoroquinolones should only be used after careful assessment of the benefits and risks and after consideration of other therapeutic options.

Read Summary

Type:

Safety Alerts (Add filter)

Source:

GOV UK (Remove filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Add filter)

Published by Medicines and Healthcare products Regulatory Agency, 11 December 2014

Further information is available to support safer use

Read Summary

Type:

Safety Alerts (Add filter)